drugset / Trial / NCT04336241
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
RP2-001-18 is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP2 in adult subjects with advanced solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Timeline
- Start
- 2019-10-17
- Primary completion
- 2026-10-31
- Completion
- 2026-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |
| Subject | RP2 | Other / unclassified | — | Other |